Aytu BioPharma: Strategic Manufacturing Transition and Financial Growth Bolster Buy Rating
TipRanksOct 27, 2023 11:26 ET
Maxim Group Initiates Coverage On Aytu BioPharma With Buy Rating, Announces Price Target of $5
BenzingaAug 9, 2023 08:41 ET
Aytu BioPharma Analyst Ratings
BenzingaAug 9, 2023 08:40 ET
HC Wainwright & Co. Reiterates Buy on Aytu BioPharma, Maintains $20 Price Target
BenzingaMay 31, 2023 07:13 ET
HC Wainwright Adjusts Price Target on Aytu BioPharma to $6 From $11, Reiterates Buy Rating
MT NewswiresJul 21, 2022 07:36 ET
Aytu BioPharma Price Target Cut to $6.00/Share From $11.00 by HC Wainwright & Co.
Dow JonesJul 21, 2022 06:51 ET
Aytu BioPharma Is Maintained at Buy by HC Wainwright & Co.
Dow JonesJul 21, 2022 06:51 ET
Aytu BioPharma analyst ratings
Benzinga Analyst RatingsJul 21, 2022 06:44 ET
HC Wainwright & Co. Maintains Buy on Aytu BioPharma, Lowers Price Target to $6
Benzinga Real-time NewsJul 21, 2022 06:44 ET
No Data
No Data